Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3a Study of Investigational MMRV Vaccine vs ProQuad as a Second Dose in Healthy Children
NCT07406360Phase 3Recruiting
- Sponsor
- GSK
- Start
- May 2026
- Primary completion
- Feb 2028
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of MMRVNS in measles, mumps, rubella and 1 more (2 arms), sponsored by GSK. Primary endpoints: Seroresponse of Immunoglobulin G (IgG) concentrations against measles at Day 43, Seroresponse of Immunoglobulin G (IgG) concentrations against mumps at Day 43 and 6 more. Started May 2026; status: recruiting.
02
Drugs
MMRVNS
03
Conditions
measlesmumpsrubellavaricella (VZV)
Beyond the preview
Go deeper on NCT07406360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07406360.